Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy

Encorafenib plus binimetinib combination therapy is one of the first-line therapies for advanced melanoma, and it is known to cause a different profile of adverse events (AEs) than dabrafenib plus trametinib combination therapy. Of such AEs, tubulointerstitial nephritis caused by BRAF plus MEK inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Kambayashi, Yumi, Ohuchi, Kentaro, Chiba, Hiromu, Tamabuchi, Erika, Nagasawa, Tasuku, Asano, Yoshihide, Fujimura, Taku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149537/
https://www.ncbi.nlm.nih.gov/pubmed/35702675
http://dx.doi.org/10.1159/000524013
_version_ 1784717223873478656
author Kambayashi, Yumi
Ohuchi, Kentaro
Chiba, Hiromu
Tamabuchi, Erika
Nagasawa, Tasuku
Asano, Yoshihide
Fujimura, Taku
author_facet Kambayashi, Yumi
Ohuchi, Kentaro
Chiba, Hiromu
Tamabuchi, Erika
Nagasawa, Tasuku
Asano, Yoshihide
Fujimura, Taku
author_sort Kambayashi, Yumi
collection PubMed
description Encorafenib plus binimetinib combination therapy is one of the first-line therapies for advanced melanoma, and it is known to cause a different profile of adverse events (AEs) than dabrafenib plus trametinib combination therapy. Of such AEs, tubulointerstitial nephritis caused by BRAF plus MEK inhibitors combination therapy is limited. In this report, a case of tubulointerstitial nephritis that developed in a rheumatoid arthritis patient with advanced melanoma treated with encorafenib plus dabrafenib combination therapy is presented.
format Online
Article
Text
id pubmed-9149537
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-91495372022-06-13 Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy Kambayashi, Yumi Ohuchi, Kentaro Chiba, Hiromu Tamabuchi, Erika Nagasawa, Tasuku Asano, Yoshihide Fujimura, Taku Case Rep Oncol Case Report Encorafenib plus binimetinib combination therapy is one of the first-line therapies for advanced melanoma, and it is known to cause a different profile of adverse events (AEs) than dabrafenib plus trametinib combination therapy. Of such AEs, tubulointerstitial nephritis caused by BRAF plus MEK inhibitors combination therapy is limited. In this report, a case of tubulointerstitial nephritis that developed in a rheumatoid arthritis patient with advanced melanoma treated with encorafenib plus dabrafenib combination therapy is presented. S. Karger AG 2022-05-02 /pmc/articles/PMC9149537/ /pubmed/35702675 http://dx.doi.org/10.1159/000524013 Text en Copyright © 2022 by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Kambayashi, Yumi
Ohuchi, Kentaro
Chiba, Hiromu
Tamabuchi, Erika
Nagasawa, Tasuku
Asano, Yoshihide
Fujimura, Taku
Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy
title Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy
title_full Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy
title_fullStr Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy
title_full_unstemmed Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy
title_short Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy
title_sort tubulointerstitial nephritis in an advanced melanoma patient treated with encorafenib plus binimetinib combination therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149537/
https://www.ncbi.nlm.nih.gov/pubmed/35702675
http://dx.doi.org/10.1159/000524013
work_keys_str_mv AT kambayashiyumi tubulointerstitialnephritisinanadvancedmelanomapatienttreatedwithencorafenibplusbinimetinibcombinationtherapy
AT ohuchikentaro tubulointerstitialnephritisinanadvancedmelanomapatienttreatedwithencorafenibplusbinimetinibcombinationtherapy
AT chibahiromu tubulointerstitialnephritisinanadvancedmelanomapatienttreatedwithencorafenibplusbinimetinibcombinationtherapy
AT tamabuchierika tubulointerstitialnephritisinanadvancedmelanomapatienttreatedwithencorafenibplusbinimetinibcombinationtherapy
AT nagasawatasuku tubulointerstitialnephritisinanadvancedmelanomapatienttreatedwithencorafenibplusbinimetinibcombinationtherapy
AT asanoyoshihide tubulointerstitialnephritisinanadvancedmelanomapatienttreatedwithencorafenibplusbinimetinibcombinationtherapy
AT fujimurataku tubulointerstitialnephritisinanadvancedmelanomapatienttreatedwithencorafenibplusbinimetinibcombinationtherapy

Ejemplares similares